Breast cancer: review of platinum-based cooperative group trials.
Platinum-based therapy has not traditionally played a significant clinical role in breast cancer in the metastatic, adjuvant, or neoadjuvant settings. Recent clinical studies, however, suggest that regimens of taxane/platinum/trastuzumab are effective option for first-line treatment of HER2-overexpressing metastatic disease, and that docetaxel/carboplatin is viable in first-line treatment of HER2-negative metastatic disease, as well as in neoadjuvant therapy of locally advanced breast cancer. Further evaluation of platinum-based regimens in large multicenter studies is warranted, and several such studies are currently in progress.
Pegram
Mark
M
Women's Cancer Program, UCLA/Johnson Comprehensive Cancer Center, UCLA/Geffen School of Medicine, Los Angeles, California 90095-1678, USA. mpegram@ucla.edu
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D043823:Taxoids; D016190:Carboplatin; D000068878:Trastuzumab